BRPI0416906A - proteinúria tubular como um indicador para risco cardiovascular elevado - Google Patents

proteinúria tubular como um indicador para risco cardiovascular elevado

Info

Publication number
BRPI0416906A
BRPI0416906A BRPI0416906-9A BRPI0416906A BRPI0416906A BR PI0416906 A BRPI0416906 A BR PI0416906A BR PI0416906 A BRPI0416906 A BR PI0416906A BR PI0416906 A BRPI0416906 A BR PI0416906A
Authority
BR
Brazil
Prior art keywords
indicator
cardiovascular risk
tubular
tubular proteinuria
elevated cardiovascular
Prior art date
Application number
BRPI0416906-9A
Other languages
English (en)
Inventor
Joachim Schrader
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0416906A publication Critical patent/BRPI0416906A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROTEINúRIA TUBULAR COMO UM INDICADOR PARA RISCO CARDIOVASCULAR ELEVADO". A presente invenção refere-se ao uso de um inibidor ACE ou de um antagonista receptor de angiotensina, para a preparação de uma composição farmacêutica para reduzir proteinúria tubular e/ou <244>~ 1~-microglobulina em um indivíduo humano não-diabético, a fim de reduzir o risco de um evento cardiovascular.
BRPI0416906-9A 2003-11-26 2004-11-26 proteinúria tubular como um indicador para risco cardiovascular elevado BRPI0416906A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027312 2003-11-26
PCT/EP2004/013511 WO2005051379A1 (en) 2003-11-26 2004-11-26 Tubular proteinuria as an indicator for elevated cardiovascular risk

Publications (1)

Publication Number Publication Date
BRPI0416906A true BRPI0416906A (pt) 2007-01-16

Family

ID=34626378

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416906-9A BRPI0416906A (pt) 2003-11-26 2004-11-26 proteinúria tubular como um indicador para risco cardiovascular elevado

Country Status (10)

Country Link
US (2) US20060264488A1 (pt)
EP (1) EP1689386A1 (pt)
JP (1) JP2007513884A (pt)
KR (1) KR20060110306A (pt)
CN (1) CN1882331A (pt)
AU (1) AU2004292775A1 (pt)
BR (1) BRPI0416906A (pt)
CA (1) CA2547124A1 (pt)
IL (1) IL175792A0 (pt)
WO (1) WO2005051379A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347788B (es) * 2007-02-12 2017-05-12 A1M Pharma Ab Diagnosis y tratamiento de preeclampsia.
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
MX357656B (es) * 2012-09-05 2018-07-18 A1M Pharma Ab Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
CN103903553A (zh) * 2014-03-14 2014-07-02 四川虹欧显示器件有限公司 一种解决高Xe含量下画面切换后低放电的方法

Also Published As

Publication number Publication date
US20070191446A1 (en) 2007-08-16
CN1882331A (zh) 2006-12-20
AU2004292775A1 (en) 2005-06-09
EP1689386A1 (en) 2006-08-16
IL175792A0 (en) 2008-04-13
JP2007513884A (ja) 2007-05-31
US20060264488A1 (en) 2006-11-23
KR20060110306A (ko) 2006-10-24
WO2005051379A1 (en) 2005-06-09
CA2547124A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
MX384206B (es) Formulaciones de inhibidores de dpp iv
WO2007038138A3 (en) Amido compounds and their use as pharmaceuticals
WO2006020598A3 (en) Amido compounds and their use as pharmaceuticals
SG151329A1 (en) Amido compounds and their use as pharmaceuticals
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2006012227A3 (en) Amido compounds and their use as pharmaceuticals
TW200621763A (en) Lactam compounds and their use as pharmaceuticals
CL2007002017A1 (es) Compuestos derivados de [4,5&#39;]-bipirimidinil-6,4&#39;-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
WO2006012226A3 (en) N-substituted piperidines and their use as pharmaceuticals
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0811180A2 (pt) Uso de probióticos ou uma mistura dos mesmos para a preparação de composição farmacêutica utilizável em um ambiente pré e/ou pós-cirúrgico.
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BR0210720A (pt) Composto e uso do mesmo
BRPI0519656A2 (pt) terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
MY177591A (en) Nk1 receptor antagonist composition
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
CL2008000683A1 (es) Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de la enzima de conversion de angiotensina (ace); formulacion de dosis unitaria; y uso en el tratamiento de la diabetes.
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BRPI0416906A (pt) proteinúria tubular como um indicador para risco cardiovascular elevado
BR0308515A (pt) Combinação de um antagonista de receptor de aldosterona com ácido nicotìnico ou um derivado de ácido nicotìnico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.